Monitor upcoming Q4 2026 13F filings for continued institutional exodus. The absence of activist or hedge fund interest suggests the post-offering thesis lacks a near-term catalyst. Wasatch's large trim may signal concerns about dilution overhang or VK2735 commercialization timeline.
Executive Summary
Viking Therapeutics' Q3 2026 institutional 13F cluster shows net selling pressure: 4 asset managers trimmed positions totaling -$6.4M, while only 2 small advisors added modestly (+$170K). The selling is dominated by Wasatch Advisors, which cut 36.7% of its stake (-$5.7M). This follows the company's dilutive $225M convertible note and $258M common stock offerings in late September, which likely drove institutional rebalancing or thesis reassessment.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$6.2M
▲ Buyers (2)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Wealth Enhancement Advisory Services | ADD | +78.2% | $627.0K | $134.0K |
| Assetmark | ADD | +49.7% | $177.0K | $36.0K |
▼ Sellers (4)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Wasatch Advisors | TRIM | -36.7% | $12.2M | -$5.7M |
| Nisa Investment Advisors | TRIM | -53.8% | $175.0K | -$108.0K |
| Prime Capital Investment Advisors | TRIM | -41.1% | $448.0K | -$227.0K |
| Hb Wealth Management | TRIM | -48.3% | $504.0K | -$286.0K |
Key Facts
- Net institutional selling of ~$6.2M (4 sellers vs 2 buyers)
- Wasatch Advisors trimmed 114.6K shares (-$5.7M), the largest seller
- Buyers were small advisors: Wealth Enhancement (+$134K) and Assetmark (+$36K)
- Cluster follows two dilutive offerings in late September 2026: $225M convertible notes and $258M common stock
- All 6 institutions are asset managers (no activist, hedge fund, or family office presence)
Financial Impact
Net institutional outflow of approximately $6.2M, with Wasatch Advisors alone accounting for $5.7M of selling. Total buying was only $170K.
Risk Factors
- Dilution from $225M convertible notes and $258M stock offering may continue to pressure shares
- Institutional selling could accelerate if VK2735 clinical or regulatory milestones slip
- Low conviction from small buyers ($805K total) provides minimal support against larger sellers
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-VKTX-2026-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Institutional Cluster | $24.56 | awaiting T+1 | — | — |
Oct 21, 2026 4d ago | Press Release | $25.83 $24.40 | ▼ −5.54% | ▼ −5.01% | — |
Sep 28, 2026 27d ago | 8-K | $31.81 $32.60 | ▲ +2.48% | ▲ +2.69% | — |
Sep 24, 2026 4w ago | 424B5 | $35.56 $33.03 | ▲ +7.11% | ▲ +6.37% | — |
Sep 24, 2026 4w ago | 424B5 | $35.56 $33.03 | ▲ +7.11% | ▲ +6.37% | — |
Sep 23, 2026 4w ago | 424B5 | $36.75 $35.56 | ▼ −3.24% | ▼ −3.78% | — |
Sep 23, 2026 4w ago | 424B5 | $36.75 $35.56 | ▲ +3.24% | ▲ +3.78% | — |
Sep 22, 2026 4w ago | 8-K | $40.85 $41.65 | ▲ +1.96% | ▲ +2.68% | — |
Jul 29, 2026 12w ago | Insider Cluster | $33.11 $31.74 | ▼ −4.14% | ▼ −4.86% | — |
Jul 29, 2026 12w ago | Insider Cluster | $33.11 $31.74 | ▼ −4.14% | ▼ −4.84% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers